{
  "report_rows": [
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$9.70 vs. cons $9.55",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$104.4B vs. cons $104.14B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Oncology & Multispecialty operating profit",
      "prediction": "BEAT",
      "answer": "pred ~$382M vs. cons $375.3M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY27 adjusted EPS (FY27)",
      "prediction": "UNCHANGED",
      "answer": "guide $43.80-$44.60 vs. cons $44.25",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY27 free cash flow (FY27)",
      "prediction": "BETTER",
      "answer": "guide $4.5-$4.9B vs. cons $4.58B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "GLP-1 / pricing commentary (FY27)",
      "prediction": "UNCHANGED",
      "answer": "guide continued growth / no profit impact vs. cons UNVERIFIED",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -2.5,
  "day1_confidence": "LOW",
  "day5_residual_pct": -3.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 mild FY estimate pressure",
  "day5_confidence": "LOW"
}